SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 1, 2020

Study Completion Date

July 1, 2020

Conditions
Soft Tissue SarcomaBone Sarcoma
Interventions
DRUG

Pembrolizumab

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

15232

UPMC Hillman Cancer Center, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

20010

Medstar Health Research Institute, Washington D.C.

27705

Duke University, Durham

32224

Mayo Clinic Florida, Jacksonville

33612

H. Lee Moffitt Cancer Center, Tampa

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic Cancer Center, Rochester

63110

Washington University in St. Louis, St Louis

90033

University of Southern California, Los Angeles

97201

Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sarcoma Alliance for Research through Collaboration

OTHER

NCT02301039 - SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | Biotech Hunter | Biotech Hunter